Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Bought by Vanguard Group Inc.

Vanguard Group Inc. increased its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 5.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,957,109 shares of the company's stock after acquiring an additional 100,691 shares during the period. Vanguard Group Inc. owned approximately 4.83% of Keros Therapeutics worth $30,981,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of KROS. AlphaQuest LLC boosted its position in shares of Keros Therapeutics by 469.0% during the 4th quarter. AlphaQuest LLC now owns 3,596 shares of the company's stock worth $57,000 after purchasing an additional 2,964 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of Keros Therapeutics in the fourth quarter valued at about $90,000. Exchange Traded Concepts LLC purchased a new stake in Keros Therapeutics during the fourth quarter worth about $99,000. China Universal Asset Management Co. Ltd. increased its holdings in Keros Therapeutics by 19.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company's stock valued at $136,000 after buying an additional 1,372 shares in the last quarter. Finally, Handelsbanken Fonder AB lifted its position in shares of Keros Therapeutics by 11.3% during the 4th quarter. Handelsbanken Fonder AB now owns 10,800 shares of the company's stock valued at $171,000 after acquiring an additional 1,100 shares during the period. Hedge funds and other institutional investors own 71.56% of the company's stock.

Keros Therapeutics Trading Up 4.0 %

Shares of NASDAQ KROS traded up $0.54 on Friday, reaching $14.07. 1,347,070 shares of the company traded hands, compared to its average volume of 785,638. The company has a 50 day moving average of $11.17 and a 200 day moving average of $29.24. Keros Therapeutics, Inc. has a fifty-two week low of $9.12 and a fifty-two week high of $72.37. The stock has a market capitalization of $570.71 million, a PE ratio of -2.70 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share for the quarter, beating analysts' consensus estimates of ($1.36) by $0.22. The company had revenue of $3.04 million for the quarter, compared to analyst estimates of $37.32 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. As a group, research analysts expect that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Insider Activity

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc bought 934,258 shares of the business's stock in a transaction dated Wednesday, April 9th. The shares were acquired at an average price of $10.13 per share, with a total value of $9,464,033.54. Following the purchase, the insider now owns 4,392,737 shares in the company, valued at approximately $44,498,425.81. The trade was a 27.01 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 22.90% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on KROS shares. Wedbush reaffirmed a "neutral" rating and issued a $15.00 price objective on shares of Keros Therapeutics in a research note on Tuesday, April 1st. Cantor Fitzgerald lowered shares of Keros Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Tuesday, January 21st. Scotiabank dropped their target price on shares of Keros Therapeutics from $44.00 to $41.00 and set a "sector outperform" rating for the company in a report on Thursday, January 16th. Oppenheimer lowered their price target on shares of Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating on the stock in a research report on Thursday, January 16th. Finally, Piper Sandler reduced their target price on Keros Therapeutics from $40.00 to $15.00 and set an "overweight" rating on the stock in a research note on Friday, January 17th. Six equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $40.33.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.